The complaint, filed by the law firm Glancy Prongay Wolke & Rotter LLP, claims that Hims & Hers failed to disclose that it shared sensitive consumer health information with third-party advertising platforms. Furthermore, the suit alleges the company charged customers for prescriptions almost immediately after intake submissions, contradicting promises that patients would first consult with medical providers to determine appropriate treatments.
These undisclosed practices allegedly invited regulatory scrutiny and potential financial penalties for the company, rendering previous positive statements about business prospects misleading. Investors seeking to serve as lead plaintiff in this litigation must file a motion with the court no later than November 2, 2026. While the lawsuit proceeds, class members are not required to take immediate action, though those wishing to participate in the recovery effort may contact the firm to discuss their legal options.



Comments (0)
No comments yet. Be the first!